THE CHALLENGE OF FOLLOW-ON BIOLOGICS FOR TREATMENT OF MULTIPLE SCLEROSIS

被引：1
|
作者：
Rivera, Victor M.
机构：
来源：
NEUROLOGY | 2010年 / 74卷 / 10期
关键词：
D O I：
10.1212/WNL.0b013e3181d2b209
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：864 / 864
页数：1
相关论文
共 50 条
  • [21] Follow-on biologics: challenges of the 'next generation'
    Schellekens, H
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : 31 - 36
  • [22] Senators draft legislation for follow-on biologics approval
    Pharm. Technol., 2007, 8 (22):
  • [23] Quality, safety and efficacy of follow-on biologics in Japan
    Yamaguchi, Teruhide
    Arato, Teruyo
    BIOLOGICALS, 2011, 39 (05) : 328 - 332
  • [24] A GUIDE TO FOLLOW-ON BIOLOGICS AND BIOSIMILARS WITH A FOCUS ON INSULIN
    Dolinar, Richard
    Lavernia, Frank
    Edelman, Steven
    ENDOCRINE PRACTICE, 2018, 24 (02) : 195 - 204
  • [25] Demystifying the Differences: Follow-on Biologics, Biosimilars, and Generics
    Wright, Eugene E., Jr.
    Blevins, Thomas C.
    Reed, Beverly
    Pollom, Roy Daniel
    JOURNAL OF FAMILY PRACTICE, 2017, 66 (04): : S22 - S27
  • [26] The emergence of follow-on disease-modifying therapies for multiple sclerosis
    Moss, Brandon P.
    Cohen, Jeffrey A.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (12) : 1560 - 1565
  • [27] Current Regulatory and Legal Considerations for Follow-On Biologics
    Kingham, R. F.
    Lietzan, E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (05) : 633 - 635
  • [28] Active Surveillance of Follow-on Biologics: A Prescription for Uptake
    Sarpatwari, Ameet
    Gagne, Joshua J.
    Levidow, Nicole L.
    Kesselheim, Aaron S.
    DRUG SAFETY, 2017, 40 (02) : 105 - 108
  • [29] Manufacturing issues shape follow-on biologics debate
    Wechsler, Jill
    Pharmaceutical Technology, 2007, 31 (06) : 30 - 40
  • [30] Active Surveillance of Follow-on Biologics: A Prescription for Uptake
    Ameet Sarpatwari
    Joshua J. Gagne
    Nicole L. Levidow
    Aaron S. Kesselheim
    Drug Safety, 2017, 40 : 105 - 108
12345